Relapsed/Refractory Multiple Myeloma Treatment Improves Progression-Free Survival in Study

Elotuzumab with pomalidomide and low-dose dexamethasone met its primary endpoint in showing a statistically significant, clinically meaningful improvement in progression-free survival in patients with relapsed/refractory multiple myeloma.

During the European Hematology Association’s 23rd Congress, held from June 14 to 17 in Stockholm, Sweden, researchers announced that the ELOQUENT-3 phase 2 study, evaluating e

lotuzumab with pomalidomide and low-dose dexamethasone (EPD) in patients with relapsed/refractory multiple myeloma, met its primary endpoint in showing a statistically significant, clinically meaningful improvement in progression-free survival (PFS) in patients treated with EPD versus patients treated with PD alone.

Elotuzumab, an immunestimulatory antibody, targets Signaling Lymphocyte Activation Molecule Family member 7 (SLAMF7), which is expressed on myeloma cells as well as Natural Killer cells and plasma cells. The drug has a dual method of action: it activates the immune system through Natural Killer cells via the SLAMF7 pathway, and also targets SLAMF7 on myeloma cells.

The ELOQUENT-3 study compared the efficacy and safety EPD versus PD alone in 177 patients with RRMM who had received 2 or more previous lines of therapy. Sixty patients were randomized to receive EPD and 57 were randomized to receive PD. The median number of lines of therapy received was 3 (range, 2-8).

Click to continue reading on The American Journal of Managed Care.